| 2023/09/21 08:03:28 | |
|---|---|
| Price | |
| 253.80 EUR | |
| Difference | 2.84% (7.00) |
General attributes
| ISIN | US0311621009 |
| Symbol | AMGN |
| Exchange | Munich |
| Currency | EUR |
| Sector | Chemical / Pharmaceutical / Health |
| Security type | Stock |
| Market cap (m) | 136,327 EUR |
| Benchmark | S&P 500 |
Market data
| Bid (Bid size) | 253.60 EUR (101) |
| Ask (Ask size) | 254.60 EUR (100) |
| Open | 253.80 EUR |
| High | 253.80 EUR |
| Low | 253.80 EUR |
| Close (prev. day) | 246.80 EUR |
| VWAP | 244.24444 EUR |
| Volume (pcs) | 0 |
| Trading volume | 0.00 |
| Number of trades | 1 |
| Last size | 0 |
Futures and Options
| Related Futures | 15 |
| Related Options | - |
PDF Downloads
| Company report: AMGEN INC. |  |
Scale: ABS REL
Instrument
Add Benchmark:
Information about previous performance does not guarantee future performance.Source: FactSet
Recent research
| Date | Headline | Download | |
| 2023/09/08 |
|
Global Equity Ratings |
|
| 2023/08/22 |
|
Global Equity Ratings |
|
| 2023/08/17 |
|
Global Equity Ratings |
|
| 2023/08/09 |
|
Global Equity Ratings |
|
| 2023/07/21 |
|
Global Equity Ratings |
|
| 2023/09/21 08:03:28 | |
|---|---|
| Price | |
| 253.80 EUR | |
| Difference | 2.84% (7.00) |
General attributes
| ISIN | US0311621009 |
| Symbol | AMGN |
| Exchange | Munich |
| Currency | EUR |
| Sector | Chemical / Pharmaceutical / Health |
| Security type | Stock |
| Market cap (m) | 136,327 EUR |
| Benchmark | S&P 500 |
Market data
| Bid (Bid size) | 253.60 EUR (101) |
| Ask (Ask size) | 254.60 EUR (100) |
| Open | 253.80 EUR |
| High | 253.80 EUR |
| Low | 253.80 EUR |
| Close (prev. day) | 246.80 EUR |
| VWAP | 244.24444 EUR |
| Volume (pcs) | 0 |
| Trading volume | 0.00 |
| Number of trades | 1 |
| Last size | 0 |
Performance and Risk
| 6m | 1Y | 3Y | |
| Perf (%) | +13.39% | +7.14% | +18.11% |
| Perf (abs.) | +29.15 | +16.45 | +37.85 |
| Beta | 0.34 | 0.38 | 0.44 |
| Volatility | 21.35 | 23.24 | 22.43 |
Scale: ABS REL
Instrument
Add Benchmark:
Information about previous performance does not guarantee future performance.Source: FactSet
Price data
| Ø price 5 days | Ø volume 5 days (pcs.) | 244.08 EUR (2) |
| Ø price 30 days | Ø volume 30 days (pcs.) | 239.97 EUR (8) |
| Ø price 100 days | Ø volume 100 days (pcs.) | 218.20 EUR (28) |
| Ø price 250 days | Ø volume 250 days (pcs.) | 233.07 EUR (41) |
| YTD High | date | 257.40 EUR (2023/01/09) |
| YTD Low | date | 199.60 EUR (2023/06/02) |
| 52 Weeks High | date | 293.25 EUR (2022/11/08) |
| 52 Weeks Low | date | 199.60 EUR (2023/06/02) |
All listings for AMGEN INC.
| Exchange | Date | Time | Price | Trading volume (mio.) | Number of trades |
| Xetra | 2023/09/21 | 11:33 | 253.20 EUR | 0.06 | 13 |
| Vienna Stock Exchange | 2023/09/21 | 09:05 | 253.20 EUR | 0.00 | 1 |
| Tradegate | 2023/09/21 | 13:23 | 253.80 EUR | 0.35 | 35 |
| Stuttgart | 2023/09/21 | 09:11 | 252.00 EUR | 0.00 | 2 |
| SIX Swiss Exchange | 2022/11/14 | 17:36 | 180.00 CHF | 0.00 | 1 |
| SIX Swiss Exchange | - | - | - | 0.00 | - |
| Nasdaq | 2023/09/20 | 22:00 | 271.46 USD | 968.81 | 65,931 |
| Munich | 2023/09/21 | 08:03 | 253.80 EUR | 0.00 | 1 |
| London Stock Exchange | 2023/09/20 | 17:35 | 270.00 USD | 0.00 | 1 |
| Hong Kong Stock Exchange | 2021/02/11 | 02:20 | 1,761.00 HKD | - | - |
| Hanover | 2023/09/21 | 08:00 | 253.80 EUR | 0.00 | 1 |
| Hamburg | 2023/09/21 | 08:00 | 253.80 EUR | 0.00 | 1 |
| Frankfurt | 2023/09/21 | 10:35 | 253.00 EUR | 0.01 | 4 |
| Euronext Milan MTF Trading After Hours | 2023/03/03 | 18:13 | 216.00 EUR | 0.00 | 1 |
| Euronext Milan MTF Global Equity Market | 2023/09/21 | 13:00 | 254.00 EUR | 0.14 | 8 |
| Duesseldorf | 2023/09/21 | 12:30 | 252.80 EUR | 0.00 | 3 |
| Berlin | 2023/09/21 | 08:08 | 254.00 EUR | 0.00 | 1 |
| BX Swiss | 2023/09/15 | 18:00 | 236.149 CHF | 0.02 | 2 |
Company Logo
Contact Details
| AMGEN INC. |
| - - |
| One Amgen Center Drive - 91320-1799 Thousand Oaks |
| Telefon: +1-805-447-1000 |
| Fax: +1-805-447-1010 |
| E-mail: - |
PDF Downloads
| Company report: AMGEN INC. | |
Company Profile
Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. It operates through Human Therapeutics segment. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA. |
Members of Management Board
| Brian Druker | Member of Board of Directors |
| Michael Drake | Member of Board of Directors |
| Omar Ishrak | Member of Board of Directors |
| Robert Williams | Member of Board of Directors |
| Ronald Sugar | Member of Board of Directors |
| Tyler Jacks | Member of Board of Directors |
| Wanda Austin | Member of Board of Directors |
| Amy Miles | Member of Board of Directors |
| Charles Holley | Member of Board of Directors |
| Ellen Kullman | Member of Board of Directors |
| Greg Garland | Member of Board of Directors |
| Robert Eckert | Member of Board of Directors |
| Robert Bradway | Chairman of Managing Board |
| Darryl Sleep | Member of Executive Committee |
| David Reese | Member of Executive Committee |
| Robert Fremeau | Member of Executive Committee |
| Arvind Sood | Member of Executive Committee |
| David Piacquad | Member of Executive Committee |
| Derek Miller | Member of Executive Committee |
| Esteban Santos | Member of Executive Committee |
| Jonathan Graham | Member of Executive Committee |
| Judy Brown | Member of Executive Committee |
| Linda Louie | Member of Executive Committee |
| Lori Johnston | Member of Executive Committee |
| Mark J. Taisey | Member of Executive Committee |